Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Linezolid 600 Mg Postinterim

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05069974Phase 3Completed

Alternative Antibiotics for Syphilis

NCT01540227Terminated

Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.

Showing all 2 trials

Research Network

Common Treatments

  • Linezolid 600 Mg Postinterim1
  • Regular Treatment For Syphilis1
  • Benzathine Penicilllin G Postinterim1

Active Sponsors

  • Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia1
  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia1
  • Ottawa Hospital Research Institute1
  • CIHR Canadian HIV Trials Network1

Top Investigators

Related Conditions

  • Secondary Syphilis2
  • Syphilis2
  • Early Latent Syphilis1
  • Earlylatent Syphilis1

Activity Timeline